Exelixis (EXEL) Other Non-Current Liabilities (2010 - 2026)
Exelixis' (EXEL) quarterly Other Non-Current Liabilities came in at $117.3 million in Q2 2026, down 2.22% year-on-year from $120.0 million in Q2 2025, and up 12.36% quarter-over-quarter from $104.4 million in Q1 2026.
Exelixis (EXEL) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $117.3 million for Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities fell 2.22% year-over-year to $117.3 million in Q2 2026; TTM through Apr 2026 was $117.3 million, a 2.22% decrease from a year earlier, with the FY2026 full-year figure at $104.4 million, down 4.11% from the prior year.
- Other Non-Current Liabilities climbed to $117.3 million in Q2 2026 per EXEL's latest filing, from $104.4 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $128.6 million in Q3 2025 and bottomed at $1.9 million in Q3 2022.
- The 5-year median for Other Non-Current Liabilities is $96.1 million (2024), against an average of $82.1 million.
- Across the five-year window, Other Non-Current Liabilities tumbled 53.35% in 2022 and surged 3129.35% in 2023, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $68.5 million in 2022, then surged by 37.49% to $94.2 million in 2023, then rose by 1.95% to $96.1 million in 2024, then climbed by 17.22% to $112.6 million in 2025, then climbed by 4.19% to $117.3 million in 2026.
- Per Business Quant, the three latest EXEL Other Non-Current Liabilities figures stand at $117.3 million (Q2 2026), $104.4 million (Q1 2026), and $112.6 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 117.33 Mn |
| Jan 2, 2026 | 104.42 Mn |
| Oct 3, 2025 | 112.61 Mn |
| Jul 4, 2025 | 128.59 Mn |
| Apr 4, 2025 | 120.00 Mn |
| Jan 3, 2025 | 108.90 Mn |
| Sep 27, 2024 | 96.07 Mn |
| Jun 28, 2024 | 109.67 Mn |
| Mar 29, 2024 | 101.27 Mn |
| Dec 29, 2023 | 94.22 Mn |
| Sep 29, 2023 | 61.62 Mn |
| Jun 30, 2023 | 73.50 Mn |
| Mar 31, 2023 | 67.38 Mn |
| Dec 30, 2022 | 68.53 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jul 1, 2022 | 17.40 Mn |
| Apr 1, 2022 | 12.52 Mn |
| Dec 31, 2021 | 8.02 Mn |
| Oct 1, 2021 | 4.09 Mn |
| Jul 2, 2021 | 7.07 Mn |